Fangzhou Inc, a pioneer in internet healthcare solutions, announced a strategic alliance with Bristol Myers Squibb (BMS) China, a global biopharmaceutical company with a robust research and development pipeline in oncology, hematology, immunology, fibrosis, and cardiovascular diseases. The partnership was officially formalized with the signing of a collaboration agreement by Dr. Xie Fangmin, founder, chairman, and CEO of Fangzhou, and Wen Yizhong, the head of the Innovative Medicines Division at BMS China and General Manager for Bristol Myers Squibb, Hong Kong.
This strategic alliance aims to drive innovation in tnternet healthcare by emphasizing the development of cutting-edge digital medical platforms and models for Internet-based chronic disease care delivery. The collaboration will also focus on in-depth collaboration around two of BMS' newest products in China, Reblozyl, a recombinant fusion protein indicated for the treatment of ß-thalassemia and Sotyktu, a selective, allosteric TYK2 inhibitor indicated for the treatment of plaque psoriasis.
Dr. Xie Fangmin remarked, ""With Fangzhou's strong technological capabilities and BMS' extensive research and development expertise, this collaboration marks an exciting new opportunity to advance digital healthcare."" Wen Yizhong highlighted the strong collaborative foundation established with Fangzhou in the past and expressed his optimism that the strategic partnership will produce lasting benefits, achieving a 1+1>2 effect that propels innovative development within the industry.
Looking ahead, Fangzhou and Bristol Myers Squibb will leverage their exceptional expertise in digital innovation, seamless omnichannel collaboration, and comprehensive chronic disease management services to establish a dynamic partnership. Together, they aim to build a strong and healthy future for the rapidly growing internet medical industry in China, pioneering new frontiers and raising standards in healthcare technology and services.